Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin-induced asthma murine model

European Journal of Pharmacology
Hyun Jeong KwakHyae Gyeong Cheon

Abstract

Phosphodiesterase-4 (PDE-4) is responsible for metabolizing adenosine 3',5'-cyclic monophosphate that reduces the activation of a wide range of inflammatory cells including eosinophils. PDE-4 inhibitors are under development for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease. Herein, we report a novel PDE-4 inhibitor, PDE-423 (3-[1-(3-cyclopropylmethoxy-4-difluoromethoxybenzyl)-1H-pyrazol-3-yl]-benzoic acid), which shows good in vitro and in vivo oral activities. PDE-423 exhibited in vitro IC(50)s of 140 nM and 550 nM in enzyme assay and cell-based assay, respectively. In vivo study using ovalbumin-induced asthmatic mice revealed that PDE-423 reduced methacholine-stimulated airway hyperreactivity in a dose-dependent manner by once daily oral administration (ED(50)=18.3 mg/kg), in parallel with decreased eosinophil peroxidase activity and improved lung histology. In addition, PDE-423 was effective in diminishing lipopolysaccharide-induced neutrophilia in vivo as well as in vitro. Oral administration of PDE-423 (100 mg/kg) had no effect on the duration of xylazine/ketamine-induced anesthesia and did not induce vomiting incidence in ferrets up to the dose of 1000 mg/kg. The present s...Continue Reading

References

Aug 7, 1986·European Journal of Pharmacology·H H SchneiderJ Seidler
Oct 1, 1993·The American Review of Respiratory Disease·P J Barnes, S Pedersen
Oct 6, 1997·American Journal of Respiratory and Critical Care Medicine·E HamelmannE W Gelfand
Feb 26, 1998·American Journal of Respiratory and Critical Care Medicine·T J Torphy
Mar 8, 2000·International Archives of Allergy and Immunology·I C CrockerR G Townley
Jun 7, 2000·Proceedings of the National Academy of Sciences of the United States of America·G HansenM Conti
Dec 15, 2000·Neuropharmacology·A RobichaudC C Chan
Jun 8, 2002·Current Pharmaceutical Design·Catherine Burnouf, Marie-Pierre Pruniaux
Apr 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Yu ZhaoJames M O'Donnell
Jan 4, 2006·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·H J KwakH G Cheon
Jul 8, 2008·European Journal of Pharmacology·Hyun Jeong KwakHyae Gyeong Cheon
Sep 2, 2008·The European Respiratory Journal·D R TaylorH K Reddel
Oct 5, 2010·Nature Reviews. Drug Discovery·Leonardo M FabbriPeter Kirkpatrick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.